Clinical Trials | November 27, 2025
Otsuka files FDA application for first-in-class ADHD drug
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Subscribe To Our Newsletter & Stay Updated
